Matinas BioPharma Holdings, Inc. (MTNB) |
|
0.3825 -0.016 (-4.02%)
|
06-06 16:00 |
|
Open: |
0.3874 |
Pre. Close: |
0.385 |
|
High:
|
0.39 |
Low:
|
0.3754 |
|
Volume:
|
516,409 |
Market Cap:
|
83(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 4:29:19 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.66  One year: 0.8 |
| Support: |
Support1: 0.37 Support2: 0.31 |
| Resistance: |
Resistance1: 0.56 Resistance2: 0.68 |
| Pivot: |
0.4 |
| Moving Average: |
MA(5): 0.38 MA(20): 0.44
MA(100): 0.5 MA(250): 0.63 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 7.9 %D(3): 7.8 |
| RSI: |
RSI(14): 37.2 |
| 52-week: |
High: 0.93 Low: 0.37 |
| Average Vol(K): |
3-Month: 493 (K) 10-Days: 445 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MTNB ] has closed above bottom band by 12.9%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.39 - 0.39 |
0.39 - 0.39 |
|
Low:
|
0.37 - 0.37 |
0.37 - 0.38 |
|
Close:
|
0.38 - 0.38 |
0.38 - 0.39 |
|
Company Description |
|
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey. |
Headline News |
Fri, 02 Jun 2023
Matinas BioPharma Holdings, Inc. (MTNB) Stock Price Today, Quote ... - Seeking Alpha
Thu, 11 May 2023
Is it Time to Dump Matinas BioPharma Holdings Inc (MTNB) Stock After it Has Fallen 26.23% in a Week? - InvestorsObserver
Thu, 11 May 2023
Why Matinas BioPharma Stock Is Sinking Today - Yahoo Finance
Wed, 03 May 2023
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023 - Marketscreener.com
Tue, 18 Apr 2023
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID - Yahoo Finance
Wed, 22 Mar 2023
Protagenic Therapeutics says board approved 1-for-4 reverse stock ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
